Navigation Links
Mifepristone Reliable For Treating Uterine Fibroids

According to a study conducted by University of Rochester, Low doses of the drug mifepristone (also known as RU-486) shrinks the uterine fibroid tumors //and greatly improves the quality of life in women. The study results were published in the December issue of the journal, Obstetrics and Gynecology.

Leiomyoma, the medical term for uterine fibroids, affects roughly half of all women aged 35 to 49. The non-cancerous tumors cause iron-deficiency anemia due to excessive menstrual bleeding, and deeply impact the quality of life for women who have this condition. Thousands of women annually opt for hysterectomies or have the tumors removed surgically because no other medical treatment has been proven effective, the study said.

'With no approved treatment for symptomatic fibroids, this study and its findings are very significant,' said corresponding author Kevin Fiscella, M.D., M.P.H., of the Department of Family Medicine Research Program at the University of Rochester Medical Center. 'Interestingly, this is the same drug that was recently shown to prevent breast cancer in a rat model. Federal funding for research related to mifepristone should be given a high priority.'

Doctors have known from prior data that mifepristone, an antiprogestin, might help uterine fibroids. But the benefits had not been confirmed until now. The University of Rochester study is the first randomized, double blind, placebo-controlled trial of mifepristone, to establish that it can be safely used at low doses to treat uterine fibroids. Forty-two premenopausal women from western New York volunteered to participate in the clinical trial from March 2004 to March 2005.

Of the total, 22 women received mifepristone at 5 mg daily, and 20 women received an identical looking placebo pill daily, for six months. Doctors sought to evaluate physical changes as well as quality of life improvements. To assess the latter, they used a survey with a 100-point scale that as
'"/>




Page: 1 2 3

Related medicine news :

1. Sepsis Death Reported With Mifepristone – FDA Issues Warnin
2. Shortness Of Breath A More Reliable Indicator Of High Risk Cardiac Disease
3. Are Conventional Tests for Heart attacks Reliable?
4. Reliable Help For Smokers From Nicotine Patches and Former Smokers
5. Parents – Teen’s Most Reliable Source for Sex Educatin
6. Male Contraceptives-Soon to be Reliable and Reversible
7. Are Alternative Therapies A Reliable Alternative?
8. Cystatin C Test- A Reliable Test to Detect Chronic Health Risks
9. Doctors Find Internet A Reliable Tool For Diagnosing Diseases
10. Are Computer-aided Mammogram Reports Reliable?
11. Computer Software Less Reliable Than Radiologists Eyes in Detecting Cancerous Tumors
Post Your Comments:
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 1Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 12Complete Horse Genome Sequence Revealed 60783 1Complete Horse Genome Sequence Revealed 60783 2Newly revised guidelines for managing thyroid cancer published in Thyroid journal 60779 1Newly revised guidelines for managing thyroid cancer published in Thyroid journal 60779 2